InterCure Ltd. INCR INCR INCR released preliminary financial results for the third quarter of 2022, revealing record revenue estimated to be CA$39 million, 63% over the revenues of the third quarter of 2021 and sequential growth of over 6%.
Preliminary Q3 2022 Financial Highlights and Milestones
-
Eleventh consecutive quarter of growth representing an annualized run rate of over CA$155 million.
-
Revenue growth expected to continue in Q4 2022.
-
Solid demand for Canndoc's branded products and expansion of the company’s medical cannabis dispensing operations.
-
Continued expansion of the company's branded products portfolio, launching more than 10 new GMP SKUs during the quarter.
-
Continued expansion of the company's medical cannabis dedicated pharmacy chain to a of total 25 locations as of the end of the third quarter.
-
Continued execution of the company's global expansion plan.
The company plans to file its full financial results for the third quarter on November 15th , 2022.
Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.
Photo: Benzinga; Sources: courtesy of Kindel Media via Pexels
Related News
InterCure Q2 2022 Revenue Grows 119%, What About Profit?
Clever Leaves 2Q: Neutraceuticals Up, Preparing For Cannabis Flower Exports From Colombia
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.